Gastrointestinal stromal tumors

Hematology/Oncology Clinics of North America

Volumn 19, Issue 3, 2005, Pages 547-564

  Von Mehren, Margaret ^a   Watson, James C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CONTRAST MEDIUM; DACARBAZINE; DASATINIB; DOXORUBICIN; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; IMATINIB; MIDOSTAURIN; MITOMYCIN; MITOXANTRONE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; BLEEDING; BLOOD TOXICITY; CANCER SURGERY; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LEIOMYOSARCOMA; LEUKOPENIA; LIVER DISEASE; LIVER METASTASIS; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PLEURAL PAIN; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RASH; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 20444385887     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.03.010     Document Type: Review

References (67)

1. R.P. DeMatteo, M.C. Heinrich, and W.M. El-Rifai Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 5 2002 466 477
2. H. Joensuu, and L. Kindblom Gastrointestinal stromal tumors-a review Acta Orthop Scand 75 2004 62 71
3. M. Miettinen, W. El-Rifai, and L.H. Sobin Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review Hum Pathol 33 5 2002 478 483
4. F.H. Qiu, P. Ray, and K. Brown Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus EMBO J 7 4 1988 1003 1011
5. S. Hirota, K. Isozaki, and Y. Moriyama Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580
6. R.P. DeMatteo, J.J. Lewis, and D. Leung Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 1 2000 51 58
7. V.C. Broudy Stem cell factor and hematopoiesis Blood 90 4 1997 1345 1364
8. B. Chabot, D. Stephenson, and V. Chapman The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus Nature 335 1988 88 89
9. J.J. Rumessen, H.B. Mikkelsen, and L. Thuneberg Ultrastructure of interstitial cells of Cajal associated with deep muscular plexus of human small intestine Gastroenterology 102 1992 56 68
10. J.D. Huizinga, L. Thuneberg, and M. Kluppel W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity Nature 373 1995 347 349
11. J.K. Chan Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anat Pathol 6 1 1999 19 40
12. S. Hirota, K. Isozaki, and T. Nishida Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract J Gastroenterol 35 Suppl 12 2000 75 79
13. C.D. Fletcher, J.J. Berman, and C. Corless Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 5 2002 459 465
14. M.C. Heinrich, C.L. Corless, and A. Duensing PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708 710
15. S. Hirota, A. Ohashi, and T. Nishida Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors Gastroenterology 125 2003 660 667
16. A. van Oosterom, I. Judson, and J. Verweij Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 38 Suppl 5 2002 S83 S87
17. G. Demetri, M. von Mehren, and C. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
18. A. Van den Abbeele, and R. Badawi Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) Eur J Cancer 38 Suppl 5 2002 S60 S65
19. M. Van Glabbeke, J. Verweij, and P. Casali Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the EORTC-STBSG, ISG and AGITG [abstract 3286] Proc Am Soc Clin Oncol 22 2003 818
20. I. Pidhorecky, R.T. Cheney, and W.G. Kraybill Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management Ann Surg Oncol 7 9 2000 705 712
21. J.A. Crosby, C.N. Catton, and A. Davis Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database Ann Surg Oncol 8 1 2001 50 59
22. J.P. Pierie, U. Choudry, and A. Muzikansky The effect of surgery and grade on outcome of gastrointestinal stromal tumors Arch Surg 136 4 2001 383 389
23. M. Rothlin, and O. Schob Laparoscopic wedge resection for benign gastric tumors Surg Endosc 15 2001 893 895
24. Y. Otani, M. Ohgami, and N. Igarashi Laparoscopic wedge resection of gastric submucosal tumors Surg Laparosc Endosc Percutan Tech 10 2000 19 23
25. M. Heinrich, C. Blanke, and B. Druker Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J Clin Oncol 20 2002 1692 1703
26. T. Lehnert Gastrointestinal sarcoma (GIST)-a review of surgical management Ann Chir Gynaecol 87 1998 297 305
27. R.P. Dematteo The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571) Ann Surg Oncol 9 2002 831 839
28. B.M. Clary, R.P. DeMatteo, and J.J. Lewis Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison Ann Surg Oncol 8 4 2001 290 299
29. S. Mudan, K. Conlon, and J. Woodruff Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection Cancer 88 2000 66 74
30. F. Eilber, G. Rosen, and C. Forscher Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas Ann Surg Oncol 6 1999 645 650
31. D.K. Rajan, M.C. Soulen, and T.W. Clark Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol chemoembolization J Vasc Interv Radiol 12 2 2001 187 193
32. S. Patel, and R. Benjamin Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors Surg Oncol 9 2000 67 70
33. P. Hohenberger, S. Bauer, and U. Schneider Tumor resection following imatinib pretreatment in GI stromal tumors [abstract 3288] Proc Am Soc Clin Oncol 22 2003 818
34. J.H. Edmonson, R.S. Marks, and J.C. Buckner Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas Cancer Invest 20 2002 605 612
35. B.E.C. Plaat, H. Hollema, and W.M. Molenaar Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins J Clin Oncol 18 18 2000 3211 3220
36. C.L. Coreless, J.A. Fletcher, and M.C. Heinrich Biology of gastrointestinal stromal tumors J Clin Oncol 15 2004 3813 3825
37. E. Buchdunger, J. Zimmermann, and H. Mett Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 1 1996 100 104
38. E. Buchdunger, C.L. Cioffi, and N. Law Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 1 2000 139 145
39. M.C. Heinrich, D.J. Griffith, and B.J. Druker Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 3 2000 925 932
40. A. van Oosterom, I. Judson, and J. Verweij Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 2001 1421 1423
41. J. Verweij, A. Van Oosterom, and J. Blay Imatinib mesylate is an active agent for GIST but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target Eur J Cancer 39 2003 2006 2011
42. J. Verweij, P.G. Casali, and J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 9440 2004 1127 1134
43. R. Benjamin, C. Rankin, and C. Fletcher Phase III dose-randomized study of imatinib mesylate (IM) for GIST: Intergroup S0033 early results [abstract 3271] Proc Am Soc Clin Oncol 22 2003 814
44. B.J. Druker, M. Talpaz, and D.J. Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 14 2001 1031 1037
45. B.J. Druker, C.L. Sawyers, and H. Kantarjian Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 14 2001 1038 1042
46. M. von Mehren, C. Blanke, and H. Joensuu High incidence of durable responses induced by Imatinib mesylate (Gleevec™) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs) Proc Am Soc Clin Oncol 21 2002 1608a
47. A. Van den Abbeele F18-FDG-PET provides evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST) Proc Am Soc Clin Oncol 2001 1444a
48. H. Choi, C. Charnsangavej, and H. Macapinlac Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate [abstract 3] Proc Am Soc Clin Oncol 22 2003 819
49. G. Demetri, M. von Mehren, and H. Joensuu Lack of Progression is the most clinically significant measure of a patient's clinical benefit: Correlating the effects of imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) with survival benefits. Proceedings of the European Society of Medical Oncology 2004 European Society of Medical Oncology Vienna (Austria)
50. C. Rankin, M. von Mehren, and C. Blanke Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase III Sarcoma Group Study S0033 Proc Am Soc Clin Oncol 22 2004 9005a
51. J. Blay, P. Berthaud, and D. Perol Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group Proc Am Soc Clin Oncol 22 2004 9006a
52. C.D. Mol, D.R. Dougan, and T.R. Schneider Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J Biol Chem 279 2004 31655 31663
53. J. Lasota, M. Jasinski, and M. Sarlomo-Rikala Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas Am J Pathol 154 1 1999 53 60
54. J. Lasota, A. Wozniak, and M. Sarlomo-Rikala Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases Am J Pathol 157 4 2000 1091 1095
55. B. Rubin, S. Singer, and C. Tsao Activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res 61 2001 8118 8121
56. M. Heinrich, C. Corless, and C. Blanke KIT mutational status predicts response to STI571 in patients with metastatic gastrointestinal tumors (GISTs) Proc Am Soc Clin Oncol 21 2002 6a
57. M. Heinrich, C. Corless, and G. Demetri Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342 4349
58. G. Demetri, C. Rankin, and C. Fletcher Phase III dose-randomized study of imatinib mesylate (Gleevec, sti571) for GIST: Intergroup S0033 early results Proc Am Soc Clin Oncol 21 2002 1651a
59. E. Tamborini, L. Bonadiman, and A. Greco A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 2004 294 299
60. A. Van Oosterom, H. Dumez, and J. Desai Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM Proc Am Soc Clin Oncol 22 2004 3002a
61. P. Reichardt, P. Pink, and T. Lindner A phase I/II trial of the oral PKC inhibitor PKC412 and imatinib mesylate in patients with gastrointestinal stromal tumors (GIST) refractory to imatinib (IM) 2004 European Society of Medical Oncology Vienna (Austria)
62. G. Demetri, S. George, and M.C. Heinrich Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate [abstract 3273] Proc Am Soc Clin Oncol 22 2003 814
63. G.D. Demetri, J. Desai, and J.A. Fletcher SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) Proc Am Soc Clin Oncol 23 2004 3001a
64. M. Heinrich, C. Corless, and M. von Mehren PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST) [abstract 3274] Proc Am Soc Clin Oncol 22 2003 815
65. N. Shah, C. Tran, and F. Lee Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
66. C. Sawyers, N. Shah, and H. Kantarjian Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myelogenous leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354835: results from a phase I dose escalation study Blood 104 11 2004 1a
67. R. Takahashi, S. Tanaka, and Y. Kitadai Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach Oncology 64 3 2003 266 274